title: [Treatment of Mild-to-moderate Bronchial Asthma (Heat Wheezing Syndrome) Patients at Acute Onset with Western Medicine Combined Danlong Oral Liquid: a Multi-center, Randomized Double- blinded, Positive-controlled Clinical Trial].
abstract: OBJECTIVE
  To observe the efficacy and safety of Danlong Oral Liquid (DOL) combined Western medicine (WM) in treating mild-to-moderate bronchial asthma patients (heat wheezing syndrome) at acute onset.
  
  
  METHODS
  Totally 480 mild-to-moderate bronchial asthma patients (heat wheezing syndrome) at acute onset were randomly assigned to two groups in the ratio 3:1, the treatment group (360 cases) and the control group (120 cases). All patients received basic WM treatment. Patients in the treatment group took DOL, 10 mL each time, 3 times per day for 7 days in total, while those in the control group took Kechuanning Oral Liquid (KOL) , 10 mL each time, 3 times per day for 7 days in total. Efficacy for asthma symptoms, lung functions and scores of TCM syndrome and/or main symptoms were evaluated.
  
  
  RESULTS
  The percentage of clinical control and significant effectiveness of asthma symptoms in the treatment group was significantly higher than that of the control group (77.36% vs 56.07%, P < 0.01). The percentage of clinical control and significant effectiveness of lung functions in the treatment group was significantly higher than that of the control group (74.28% vs 50.00%, P < 0.01). The anterior-posterior difference in scores of TCM syndrome was significantly superior in the treatment group than in the control group (-11.26 ± 4.70 vs -9.21 ± 5.09, P < 0.01). The anterior-posterior difference in scores of main symptoms was significantly better in the treatment group than in the control group (-6.58 ± 3.08 vs -5.16 ± 3.45, P < 0.01). The incidence of adverse reactions was significantly lower in the treatment group than in the control group [1.73% (6/346 cases) vs 10.17% (12/118 cases) , P < 0.05].
  
  
  CONCLUSIONS
  DOL combined WM was superior to KOL in treating mild-to-moderate bronchial asthma patients (heat wheezing syndrome) at acute onset.
authors.forename: Min
authors.initials: M
authors.lastname: Liu
authors.forename: Gui-ying
authors.initials: GY
authors.lastname: Liu
authors.forename: Si-yuan
authors.initials: SY
authors.lastname: Hu
authors.forename: Li-ling
authors.initials: LL
authors.lastname: Wan
authors.forename: Hong-yan
authors.initials: HY
authors.lastname: Cai
authors.forename: Yan-ling
authors.initials: YL
authors.lastname: Xu
authors.forename: Bing
authors.initials: B
authors.lastname: Mao
authors.forename: Mu-yun
authors.initials: MY
authors.lastname: Zhu
authors.forename: Li-ying
authors.initials: LY
authors.lastname: Cui
authors.forename: Jian-min
authors.initials: JM
authors.lastname: Sun
mesh_terms: D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D035843:Biomedical Research; D004359:Drug Therapy, Combination / Q000379:methods; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use*; D006358:Hot Temperature; D006801:Humans; D008168:Lung; D008516:Medicine, Chinese Traditional; D008517:Phytotherapy; D012135:Respiratory Sounds; D013577:Syndrome
chemical_list: D018927:Anti-Asthmatic Agents; D004365:Drugs, Chinese Herbal